<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601168</url>
  </required_header>
  <id_info>
    <org_study_id>kneeSOFT100</org_study_id>
    <nct_id>NCT04601168</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety and Performance of a Compression Knee Support in the Prevention of Injuries During Sports Practice</brief_title>
  <official_title>Assessment of the Safety and Performance of a Compression Knee Support in the Prevention of Injuries During Sports Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Decathlon SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EFOR, France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Decathlon SE</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decathlon has developed kneeSOFT100 product which is medical device designed to reduce pain&#xD;
      and joint instability during sport practice. The objective of this multicentre study is to&#xD;
      collect data on the related clinical complications and clinical outcomes of market-approved&#xD;
      Decathlon kneeSOFT100 product to demonstrate safety and performance of this device in a&#xD;
      real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional score</measure>
    <time_frame>6 weeks of follow-up</time_frame>
    <description>Comparison of the functional result (Lysholm Score: 0-100 points) between the baseline and last follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confidence level</measure>
    <time_frame>At baseline and 6 weeks of follow-up</time_frame>
    <description>Gap in the confidence level (patient rated outcome with 6 questions, ranging from 0 to 100) related to physical activity, between the baseline and last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee instability</measure>
    <time_frame>At 2 weeks and 6 weeks of follow-up</time_frame>
    <description>Comparison of knee instability between the first two weeks of follow-up (without use of the device during sports sessions) and the following four weeks (with use of the device during sports sessions), measured through a visual analog scale (VAS, ranging from 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain</measure>
    <time_frame>At 2 weeks and 6 weeks of follow-up</time_frame>
    <description>Comparison of knee pain between the first two weeks of follow-up (without use of the device during sports sessions) and the following four weeks (with use of the device during sports sessions), measured through a VAS (ranging from 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events)</measure>
    <time_frame>6 weeks of follow-up</time_frame>
    <description>Rate of adverse events occurred during the study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Knee Pain</condition>
  <condition>Chronic Instability of Knee Joint</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>kneeSOFT100</intervention_name>
    <description>During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with chronic pain AND / OR chronic knee instability whose current condition of&#xD;
        his/her knee allows him/her to pursue a usual physical activity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is aged ≥18 years old&#xD;
&#xD;
          -  Subject has chronic pain AND / OR chronic knee instability&#xD;
&#xD;
          -  The current condition of his/her knee allows the subject to resume usual physical&#xD;
             activity&#xD;
&#xD;
          -  Subject has been informed and is willing to sign an informed consent form&#xD;
&#xD;
          -  Subject is willing to comply with protocol requirements and return to the study center&#xD;
             for all clinical evaluations and required follow-up (6 weeks)&#xD;
&#xD;
          -  Subject is affiliated to the French social security regime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has conditions that may interfere with his/her ability to understand protocol&#xD;
             requirements, participate in scheduled visits, or provide his/her informed consent&#xD;
&#xD;
          -  Subject has worn a support (knee brace or articulated orthosis) during sports sessions&#xD;
             during the last month&#xD;
&#xD;
          -  Subject has any medical condition that could impact the study at investigator's&#xD;
             discretion&#xD;
&#xD;
          -  Subject has a known hypersensitivity or allergy to the components of the device&#xD;
             (elastodiene, polyester)&#xD;
&#xD;
          -  Adult subject to a legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André THEVENON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional, Universitaire de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibault VIGNAIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>KOSS Paris 8</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean HEE</last_name>
    <phone>+33 (0)7 64 35 00 45</phone>
    <email>jean.hee@btwin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Thevenon, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KOSS Paris 8</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibault VIGNAIS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 4, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

